title: Association of 5α-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy.
abstract: BACKGROUND
  We investigated the association of 5α-reductase inhibitor (5-ARI) treatment with pathologic and biochemical outcome among the contemporary prostate cancer (PCa) patients undergoing radical prostatectomy.
  
  
  METHODS
  We reviewed records of 1,204 men who underwent radical prostatectomy from 2003 to 2010. We estimated association of 5-ARI use with high (≥7) pathologic Gleason score and pathologically nonorgan-confined disease (≥pT3) via logistic regression, and biochemical outcome via Cox proportional hazards regression.
  
  
  RESULTS
  Of 1,204 patients, 50 (4.2%) reported having history 5-ARI treatment before radical prostatectomy. Median duration of 5-ARI treatment among the 50 patients was 23.0 months. When adjusted for various factors including age, body mass index, prostate-specific antigen, clinical stage, biopsy Gleason, and prostate volume, history of 5-ARI treatment was revealed to be significantly associated with high (≥7) pathologic Gleason score (P = 0.015). Also, 5-ARI use was observed to significantly associated with higher rates of extraprostatic extension of tumor (P = 0.005) and seminal vesicle invasion (P = 0.003), respectively, when adjusted for same variables. However, 5-ARI use was not demonstrated to be a significant preoperative predictor of biochemical recurrence-free survival in multivariate analysis (P = 0.528).
  
  
  CONCLUSIONS
  Our results showed 5-ARI treatment may be associated with more aggressive PCa demonstrating higher pathologic Gleason score and advanced pathologic tumor stage in men undergoing radical prostatectomy. However, further investigations via larger-scale, prospective studies would be needed on the actual effect of 5-ARI treatment on PCa-specific morbidity and mortality.
authors.affiliation: Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea.
authors.forename: Sung Kyu
authors.initials: SK
authors.lastname: Hong
authors.forename: Jong Jin
authors.initials: JJ
authors.lastname: Oh
authors.forename: Sangchul
authors.initials: S
authors.lastname: Lee
authors.forename: Hak Min
authors.initials: HM
authors.lastname: Lee
authors.forename: Seok-Soo
authors.initials: SS
authors.lastname: Byun
authors.forename: Gheeyoung
authors.initials: G
authors.lastname: Choe
authors.forename: Sang Eun
authors.initials: SE
authors.lastname: Lee
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D016016:Proportional Hazards Models; D011467:Prostate / Q000187:drug effects*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D058891:5-alpha Reductase Inhibitors